Eugia Pharma Specialities Limited
Eugia Pharma Specialities Limited is a Public Non-govt company company incorporated in 2013 and based in Telangana, India. Eugia Pharma Specialities Limited operates in Chemical preparations of a kind used in textile / paper / leather industry, manu (NIC 24297) with authorized capital of ₹800.00 Cr and paid-up capital of ₹621.01 Cr. For 2023-24, the company reported revenue of ₹3150.93 Cr and profit after tax of ₹800.45 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 67/100 (grade C), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
EUGIA PHARMA SPECIALITIES LIMITED is the legal entity of eugiapharma.com.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +39d | filed |
| MGT-7 | FY2024-25 | 25 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +36d | filed |
| MGT-7 | FY2023-24 | 23 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 27 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Eugia Pharma Specialities Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 490754850 | Kotak Mahindra Bank Ltd(Bank) | ₹15.16 Cr | 04 Jul 2023 | Satisfied |
| 846467264 | Axis Bank Ltd(Bank) | ₹17.70 Cr | 04 Jul 2019 | Open |
| 182283288 | Axis Bank Ltd(Bank) | ₹6.66 Cr | 27 Jan 2023 | Satisfied |
| 886231246 | ICICI Bank Ltd(Bank) | ₹6.02 Cr | 19 Sep 2022 | Open |
| 721767346 | HDFC Bank Ltd(Bank) | ₹3.92 Cr | 27 Jan 2022 | Satisfied |
Charge IDs, lenders & amounts for Eugia Pharma Specialities Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — | ||||
| 2016-17 | — | ||||
| 2015-16 | — | ||||
| 2014-15 | — |
Detailed Financials
4 FYs| Line item | 2023-24 | 2022-23 | 2021-22 | 2020-21 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | +60.0% | +44.0% | — | |
| Profit after Tax2023-24 | +120.0% | +9512.0% | — | |
| Net Worth2023-24 | +29.0% | +47.0% | +98.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2014-15 | — | — | -0.31% | -0.13% | — | |||
| 2015-16 | — | — | -0.78% | -0.42% | — | |||
| 2016-17 | — | — | -0.42% | -0.29% | 0.42 | |||
| 2017-18 | — | — | -0.32% | -0.17% | 0.83 | |||
| 2018-19 | — | — | -0.73% | -0.28% | 1.65 | |||
| 2019-20 | -17.28% | — | -5.22% | -2.27% | 1.29 | |||
| 2020-21 | +0.04% | +183.02% | +0.02% | +0.01% | 0.69 | |||
| 2021-22 | +21.56% | +323.14% | +40.53% | +11.51% | 2.52 | |||
| 2022-23 | +13.29% | +18.34% | +22.81% | +6.63% | 2.44 | |||
| 2023-24 | +25.40% | +56.42% | +40.56% | +18.42% | 1.20 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 2,26,13,745 | 74.44% |
| Institutional Investors | 1 | 30,76,718 | 10.13% |
| Public & Others | 44 | 46,87,887 | 15.43% |
Promoter, institutional & public holding for Eugia Pharma Specialities Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
7 peersTop 10 in Chemical preparations of a kind used in textile / paper / leather industry, manu
by healthView all ›Events & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.